Home/Filings/4/0001567619-19-006613
4//SEC Filing

Hatten Sandra L 4

Accession 0001567619-19-006613

CIK 0001012477other

Filed

Mar 10, 8:00 PM ET

Accepted

Mar 11, 7:07 PM ET

Size

15.5 KB

Accession

0001567619-19-006613

Insider Transaction Report

Form 4
Period: 2019-03-07
Hatten Sandra L
See Remarks
Transactions
  • Award

    ADSs

    2019-03-07+18,00058,837 total
  • Award

    Stock Option (right to buy)

    2019-03-07$1.85/sh+80,000$148,00080,000 total
    Exercise: $1.85Exp: 2029-03-07ADSs (80,000 underlying)
Holdings
  • Stock Option (right to buy)

    Exercise: $21.67Exp: 2025-06-26ADSs (100,000 underlying)
    100,000
  • Stock Option (right to buy)

    Exercise: $14.35Exp: 2025-12-10ADSs (50,000 underlying)
    50,000
  • Stock Option (right to buy)

    Exercise: $8.95Exp: 2027-12-12ADSs (60,000 underlying)
    60,000
  • Stock Option (right to buy)

    Exercise: $10.40Exp: 2026-12-14ADSs (80,000 underlying)
    80,000
  • ADSs

    (indirect: By Spouse)
    3,400
Footnotes (9)
  • [F1]The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
  • [F2]Includes (a) 20,000 ADSs granted under the issuer's "Free Share" award program as restricted ADSs on 8/10/2016, all of which were issued to the reporting person on the second anniversary of the grant date; in connection with the payment of certain withholding taxes related to such issuance, the reporting person sold 6,290 ADSs on August 10, 2018; (b) 10,000 ADSs granted under the issuer's "Free Share" award program as restricted ADSs on 12/14/2016, all of which were issued to the reporting person on the second anniversary of the grant date; in connection with the payment of certain withholding taxes related to such issuance, the reporting person sold 3,173 ADSs on December 14, 2018; [continued in footnote 3 below]
  • [F3](c) 12,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 8,333 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 4,167 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); and (d) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary).
  • [F4]The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities. The reporting person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
  • [F5]Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 6/26/2015 grant date.
  • [F6]Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
  • [F7]Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
  • [F8]Options become exercisable as to 15,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.
  • [F9]Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 3/7/2019 grant date.

Documents

1 file

Issuer

AVADEL PHARMACEUTICALS PLC

CIK 0001012477

Entity typeother

Related Parties

1
  • filerCIK 0001600771

Filing Metadata

Form type
4
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 7:07 PM ET
Size
15.5 KB